Furthermore, hepatic SOD activity decreased when DABK was administered into NASH and interestingly, when the B1R antagonist was added, a tendency to normalize was observed, suggesting a role for B1R activation in SOD activity. The gene discussed is BDKRB1; the disease is metabolic dysfunction-associated steatohepatitis.